Search Results

PharmAbcine, Inc. announced that its U.S. subsidiary, Wincal Biopharm, Inc. (“WincalBio”), gained agreat attention at the world’s largest ophthalmology conference, Association for Research in Vision and Ophthalmology 2024 (ARVO 2024), when they presented the preclinical data of the eye drop formulation.

On the evening of May 5, Kexing Biopharm announced it had obtained a “Certificate of GMP Compliance of a Manufacturer” granted by the Norwegian Medical Products Agency in accordance with the European Medicines Agency regulations.

Adare Pharma Solutions, a technology-driven contract development and manufacturing organization, announced the acquisition of Frontida BioPharm, a vertically integrated CDMO focused on oral formulations.

TC BioPharm plc announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 1,750,000 of the Company’s American Depositary Shares originally issued in December 2023 with an exercise price of £1.5814 per ADS and a term of five years.

TC BioPharm today announced its participation at the upcoming Sequire Investor Summit 2024 scheduled for January 23-25, 2024.

TC BioPharm PLC announced the execution of a non-binding letter of intent to acquire a privately-held biotechnology company pursuing the development of innovative Chimeric Antigen Receptor T-cell therapies for the treatment of refractory cancers and solid tumors.

PharmAbcine, Inc. announced that the Company’s U.S. subsidiary, Wincal Biopharm, Inc., will present preclinical findings on its innovative ocular drug delivery platform at the upcoming conference, Association for Research in Vision and Ophthalmology, the world’s largest ophthalmology conference which will be held from May 5th to 9th, 2024 in Seattle, WA, United States.

On the 24th of May, Kexing Biopharm announced that Shenzhen Kexing Pharmaceutical Co., Ltd., its wholly-owned subsidiary, recently received a Notice of Approval for Drug Clinical Trials from the National Medical Products Administration, approving its clinical trial application for GB08 injection solution developed independently by the company.